Recent Advances in Treatment for Benign Prostatic Hyperplasia

In 2015, the treatment of benign prostatic hyperplasia (BPH) saw significant advancements driven by personalized medicine and medical technology. Personalized medicine allowed for tailored treatments based on individual genetic and physiological characteristics, while technological innovations led to less invasive procedures. Although no new prostate-specific medications were introduced, existing treatments like alpha-blockers and 5-alpha reductase inhibitors continued to be used, despite concerns about side effects. Newer medications like PDE5 inhibitors showed promise in improving BPH symptoms without adverse sexual side effects. Surgical advancements included minimally invasive techniques such as the prostatic urethral lift and prostatic artery embolization, though the latter required more rigorous data. Laser surgeries, particularly holmium laser enucleation of the prostate (HOLEP), became standard due to their efficacy and reduced morbidity. The future of BPH management was expected to focus on understanding complex interactions affecting urinary symptoms and developing novel surgical techniques like aquablation. Overall, the approach emphasized individualized treatment plans to meet diverse patient needs.